Pharmacokinetics of Perfluorobutane Following Intravenous Bolus Injection and Continuous Infusion of Sonazoid™ in Healthy Volunteers and in Patients with Reduced Pulmonary Diffusing Capacity

Landmark, Kristin Eitrem; Johansen, Per Wiik; Johnson, Judith A.; Johansen, B.V.; Uran, Steinar; Skotland, Tore

doi:10.1016/j.ultrasmedbio.2007.09.019

Cited by 62 publications

(64 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Sonazoid TM is known to be captured by the reticulo-endothelial system, after intravenous injection almost all of it remains entirely within the intravascular space without being trapped in normal small vessels. 11,[14][15][16] Furthermore, Sonazoid TM is rheologically similar to red blood cells. These characteristics of Sonazoid TM in renal CEUS imaging enable prolonged visualization of blood flow in the renal arterioles and capillaries, as demonstrated in this study.…”

Section: Discussionmentioning

confidence: 97%

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

et al. 2010

View full text Add to dashboard Cite

SummaryChronic kidney disease (CKD) is a major and serious risk factor for cardiovascular disease (CVD). Continuous hypoxia due to hypoperfusion in peritubular capillaries is one of the factors aggravating CKD, but evaluation of perfusion in this region is difficult using clinically available imaging methods. Since the second-generation ultrasound contrast agent Sonazoid TM has a stable shell, it enables visualization of the renal vasculature for a long period of time. We therefore evaluated changes in contrast-enhanced ultrasound (CEUS) imaging with Sonazoid TM in CKD patients.Sonazoid TM was used in 85 CKD patients and 5 control subjects, and images were recorded for 10 minutes. Time-intensity curves were generated from the images of 62 time points in both cortex and medulla.In control samples, contrast enhancement spread from the hilar portion to the periphery along the direction of arterial flow, and renal cortex and medulla were then enhanced in sequence. Enhancement was maximal soon after, then gradually decreased, but was still visible at 600 seconds. In CKD patients, renal contrast enhancement was attenuated in both cortex and medulla. On time-intensity curves, the attenuation of enhancement was composed of delayed rising, reduction of peak, and acceleration of decay in both cortex and medulla with progression of renal dysfunction. No side effects of the contrast agent were observed in any subjects.The attenuation of renal contrast enhancement observed in CKD patients appears to reflect disturbance of perfusion in peritubular capillaries. CEUS with Sonazoid TM is a useful and safe means of visualizing the renal microvasculature. (Int Heart J 2010; 51: 176-182)

show abstract

Section: Discussionmentioning

confidence: 97%

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

et al. 2010

View full text Add to dashboard Cite

show abstract

“…However, the portal pressures over this time are still believed to be relatively stable. Despite its excellent safety profile and daily clinical use in Japan since 2007 (33,34), the U.S. Food and Drug Administration (FDA) has yet to approve this contrast agent for clinical use. In our study, we chose to use this contrast agent because previous in vitro work showed its subharmonic amplitude to be the most sensitive to hydrostatic pressures of all commercially available agents (11).…”

Section: Ultrasonography: Noninvasive Estimation Of Hepatic Venous Prmentioning

confidence: 99%

Chronic Liver Disease: Noninvasive Subharmonic Aided Pressure Estimation of Hepatic Venous Pressure Gradient

Eisenbrey

Dave²,

Halldorsdottir³

et al. 2013

Radiology

View full text Add to dashboard Cite

Purpose:To compare subharmonic aided pressure estimation (SHAPE) with pressure catheter-based measurements in human patients with chronic liver disease undergoing transjugular liver biopsy. Materials and Methods:This HIPAA-compliant study had U.S. Food and Drug Administration and institutional review board approval, and written informed consent was obtained from all participants. Forty-five patients completed this study between December 2010 and December 2011. A clinical ultrasonography (US) scanner was modified to obtain SHAPE data. After transjugular liver biopsy with pressure measurements as part of the standard of care, 45 patients received an infusion of a microbubble US contrast agent and saline. During infusion, SHAPE data were collected from a portal and hepatic vein and were compared with invasive measurements. Correlations between data sets were determined by using the Pearson correlation coefficient, and statistical significance between groups was determined by using the Student t test. Results:-The 45 study patients included 27 men and 18 women (age range, 19-71 years; average age, 55.8 years). The SHAPE gradient between the portal and hepatic veins was in good overall agreement with the hepatic venous pressure gradient (HVPG) (R = 0.82). Patients at increased risk for variceal hemorrhage (HVPG > 12 mm Hg) had a significantly higher mean subharmonic gradient than patients with lower HVPGs (1.93 dB 6 0.61 [standard deviation] vs 21.47 dB 6 0.29, P , .001), with a sensitivity of 100% and a specificity of 81%, indicating that SHAPE may be a useful tool for the diagnosis of clinically important portal hypertension. Conclusion:Preliminary results show SHAPE to be an accurate noninvasive technique for estimating portal hypertension.q RSNA, 2013 Supplemental material: http://radiology.rsna.org/lookup /suppl

show abstract

“…Sonazoid consists of perfluorobutane microbubbles with a median diameter of 2 to 3 μm [17] . A pharmacokinetic study of Sonazoid showed that blood concentrations of perfluorobutane declined biphasically with a distribution half-life of 2 to 3 min and an elimination half-life of 30 to 45 min [18] . The special feature of Sonazoid is the Kupffer imaging in the post-vascular phase, which is stable for at least 60 min post-injection and tolerable for multiple scanning and can be obtained with low acoustic power, because Sonazoid microbubbles are phagocytosed by Kupffer cells [19] .…”

Section: Ultrasound Contrast Agents (Ucas) and Contrast-specific Techmentioning

confidence: 99%

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Wong

Xu²,

Xie³

2009

WJR

View full text Add to dashboard Cite

Patients with liver cirrhosis are at increased risk of hepatocellular carcinoma (HCC). Conventional or baseline ultrasound (BUS) is often used as the first-line tool for HCC surveillance or detection, but the accuracy of BUS in HCC detection or differentiation from other focal liver lesions (FLLs) is limited. Contrast-enhanced ultrasound (CEUS) represents a recent revolution in the field of ultrasonography and it has become increasingly important in the detection and evaluation of FLLs. In CEUS, HCC typically exhibits arterial hyper-enhancement and portal-venous washout represented by hypoenhanced lesions in the portal venous and late phases. The detection rate of HCC was significantly higher with CEUS compared with BUS. Even regenerative or some dysplastic nodules may exhibit arterial hyperenhancement as they are differentiated from HCC by its iso-enhancing pattern in portal and late phases. The contrast-enhancement patterns of other different types of benign and malignant FLLs, as well as their detection rates with CEUS, were also discussed.

show abstract

Pharmacokinetics of Perfluorobutane Following Intravenous Bolus Injection and Continuous Infusion of Sonazoid™ in Healthy Volunteers and in Patients with Reduced Pulmonary Diffusing Capacity

Cited by 62 publications

References 14 publications

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

Evaluation of Renal Microcirculation by Contrast-Enhanced Ultrasound With SonazoidTM as a Contrast Agent Comparison Between Normal Subjects and Patients With Chronic Kidney Disease

Chronic Liver Disease: Noninvasive Subharmonic Aided Pressure Estimation of Hepatic Venous Pressure Gradient

Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound

Contact Info

Product

Resources

About